Eli Lilly and Company
Budget
€900 — €0
EP Access
4
accredited persons
Staff
7
1.9 FTE
EU Grants
None
Mission & Goals
Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. Headquartered in the US, Lilly has approximately 46,913 employees worldwide. In 2024 global revenue was approx. $45.04 billion, of which 24.4% as a percentage of sales was invested in Research and Development. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years. This data will be updated as soon as new annual report is available ( approx. April 2026) ( https://investor.lilly.com/financials.cfm )
EU Legislative Interests
Revision of pharmaceutical legislation, Intellectual Property Rights and incentives – including Orphan Medicinal products, Paediatric medicines and Anti-Microbial Resistance (AMR), Free Trade Agreements – EU / US, EU / UK, EU / India, EU Beating Cancer Plan,EU Safe Hearts Plan, BioTech Acts I & II, MDR/ IVDR regulation, Critical Medicines Act, EU HTA Regulation, EU4Health, EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes, European Chemicals Agency (ECA), Packaging and Packaging Waste Regulation, REACH, Urban Waste Water Treatment Directive, per-and polyfluoroalkyl substances (PFAS), Industrial strategy (including bio-manufacturing), Life sciences strategy, Competition law, Horizon Europe, Innovative Healthcare Initiative (IHI), European Medicines Agency (EMA), Clinical Trials Regulation, Falsified Medicines Directive, Cross-border Healthcare Directive, Data Protection Regulation, Public Procurement Directive, Substances of Human Origin (SoHO), Transparency Directive, Artificial Intelligence, Digital / Digital health, European Health Data Space, EU4Health. Other policy areas of interest include Innovation, Research and Development, Public-Private Partnerships, Mergers and acquisitions, Life sciences, Biopharmaceuticals, Manufacturing including Active Pharmaceutical Ingredient (API), Health Outcomes, Real World Evidence, Pricing, Reimbursement and Market Access to medicines, Alzheimer’s disease, cardiometabolic health, cancer, diabetes, immunology, obesity, pain, healthcare sustainability, global health pandemics, clinical trials transparency, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.
Communication Activities
Represented through several trade bodies and industry associations, for example EFPIA, EuropaBio, MedTech Europe, AmChamEU. Participating in events on competitiveness - Politico competitiveness summit and health summit, trade, industrial strategy, health and life science policy, for example European Health Summit, Kangaroo Group and The Parliament magazine - Health debate Meeting with policy makers in the EU institutions. Engaging with other public policy stakeholders.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Eli Lilly and Company is a member of the following associations and bodies: European Federation of Pharmaceutical Industries and Associations (EFPIA), The European Association of Bioindustries (EuropaBio), American Chamber of Commerce to the European Union (AmChamEU), American European Community Association, Kangaroo Group, European Business Summit, MedTech Europe, Belgian Brain Council, ABC Global Alliance, Transforming Breast Cancer Together, Pharmaceutical Research and Manufacturers of America (PhRMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), European Policy Centre.
Organisation Members
European Association of Pharmaceutical Industries and Associations (EFPIA), The European Association of Bioindustries (EuropaBio), American Chamber of Commerce to the European Union (AmChamEU), Kangaroo Group, European Business Summit, MedTech Europe, Pharmaceutical Research and Manufacturers of America (PhRMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), European Policy Centre.
Additional Information
N/A
Commissioner Meetings
No recorded meetings with EU commissioners.